<DOC>
	<DOCNO>NCT01997255</DOCNO>
	<brief_summary>Sturge Weber Syndrome ( SWS ) rare disease affect patient 's brain cause benign ( non-cancerous ) tumor grow brain . One symptoms SWS epilepsy . People epilepsy seizure . Some patient may also eye problem red mark facial skin . This study do find study drug , everolimus , safe helpful effect patient SWS seizures respond current anti-epileptic medication . The study drug , everolimus ( Afinitor® ) , supply Novartis Pharmaceuticals Corporation .</brief_summary>
	<brief_title>Adjunctive Everolimus ( RAD 001 ) Therapy Epilepsy Children With Sturge-Weber Syndrome ( SWS )</brief_title>
	<detailed_description>The main study part 3 phase . The first phase call baseline phase consist 1-2 study site visit ( ) . During phase , investigator gather information subject , his/her medical history , current health . During second phase study , subject start take study drug . It take approximately 4 week find right amount study drug subject take . This process call titration phase . There 2 visit titration phase . Once subject right amount study drug , he/she take dose 12 week . This phase call maintenance phase consist 3 study site visit . At end maintenance phase , study doctor determine take everolimus help reduce number seizure subject , he/she choice continue take study drug extend time . There 4 total study site visit extension phase . Study assessment : 1 . Medical History : A detailed medical history give subject 's medical record review study team verify inclusion exclusion criterion . 2 . Vital Signs : Weight , height , blood pressure , pulse rate , body temperature , record . 3 . Physical Exam : A standard physical examination perform baseline , week 4 , 16 , month 6 12 extension visit . 4 . Neurological Exam : A standard neurological examination perform baseline , week 4 , 16 , month 6 12 extension visit . 5 . Dermatological Exam : A skin examination perform assess presence characteristic Port-wine stain birthmark . 6 . Ophthalmologic Exam : An eye examination perform evaluate presence glaucoma . Visual acuity , tonometry , visual field assess . 7 . Safety Laboratory Assessments : Safety laboratory assessment perform baseline , week 4 , week 8 , week 16 , every 3 month thereafter extension phase study . 8 . Pregnancy testing : For female child-bearing potential , serum pregnancy perform screen every visit safety laboratory assessment do . 9 . Antiepileptic Drug ( AED ) Concentrations : AED level specific subject perform baseline , week 2 , week 4 , week 8 , week 16 , every 3 month thereafter extension phase study . This test do determine blood level anti-epileptic drug participant may take . 10 . Everolimus Concentrations : Everolimus level perform start study medication week 2 , week 4 , week 8 , week 16 , every 3 month thereafter extension phase study . This test do determine dose level study drug give visit .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Brain Stem Infarctions</mesh_term>
	<mesh_term>Klippel-Trenaunay-Weber Syndrome</mesh_term>
	<mesh_term>Sturge-Weber Syndrome</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>218 year age , male female . Subject weight great equal 6 kg study entry . Subjects clinically diagnose SWS , inclusive cerebral dermatologic involvement . Ophthalmic involvement monitor present , necessary enrollment . History epilepsy history least 4 seizure month prior screen . Medically refractory epilepsy define failure two approve antiepileptic therapy . Females childbearing potential must use highly effective contraception study 8 week stop treatment . Sexually active male must use condom intercourse take study drug , 8 week stop study treatment . Adequate bone marrow function . Adequate liver function . Adequate renal function . Acceptable fast serum cholesterol fast triglyceride level . Patients currently receive anticancer therapy receive anticancer therapy within 4 week start Everolimus ( include chemotherapy , radiation therapy , antibody base therapy , etc. ) . Known intolerance hypersensitivity Everolimus rapamycin analog . Known impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral Everolimus . Uncontrolled diabetes mellitus despite adequate therapy . Patients severe and/or uncontrolled medical condition . Chronic treatment corticosteroid immunosuppressive agent . Topical inhale corticosteroid allow . Known history HIV seropositivity . Patients receive live attenuate vaccine within 1 week start Everolimus study . Patients history another primary malignancy , exception : nonmelanoma skin cancer , carcinoma situ cervix , uterus , breast patient disease free ≥3 year . Patients history noncompliance medical regimen consider potentially unreliable able complete entire study . Patients currently part participate clinical investigation investigational drug within 1 month prior dose . Pregnant nursing ( lactate ) woman .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Everolimus</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Sturge Weber Syndrome</keyword>
	<keyword>Port wine stain</keyword>
	<keyword>Glaucoma</keyword>
</DOC>